Author

Thierry Duvauchelle

Observed names: T Duvauchelle, T. Duvauchelle, THIERRY DUVAUCHELLE

Observed institutions: ASTER, Bioprojet (France)

ORCID: 0000-0002-4762-588X

Observed ORCID: 0000-0002-4762-588X

OpenAlex ID: A5084662929

Single-Dose Clinical Pharmacokinetic Studies of Gefitinib

2005 · Helen C Swaisland, Robert P Smith, et al. · Clinical Pharmacokinetics · 142

First Pharmacokinetic—Pharmacodynamic Study in Humans with a Selective 5‐Hydroxytryptamine4 Receptor Agonist

1997 · Silke Appel, Anette Kumle, et al. · The Journal of Clinical Pharmacology · 69

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

2011 · Paul Martin, Stuart Oliver, et al. · Drugs in R&D · 51

Bioavailability and Cardiovascular Effects of Adrenaline Administered by Anapen Autoinjector in Healthy Volunteers

2017 · Thierry Duvauchelle, Philippe Robert, et al. · The Journal of Allergy and Clinical Immunology In Practice · 50

PDF

Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study

2023 · Antoine Tarral, Lionel Hovsepian, et al. · Clinical Pharmacokinetics · 35

PDF

Absence of Interaction of Fondaparinux Sodium with Aspirin and Piroxicam in Healthy Male Volunteers

2002 · C??line Ollier, Richard A. Faaij, et al. · Clinical Pharmacokinetics · 31

Pharmacokinetics of pitolisant in children and adolescents with narcolepsy

2019 · Michel Lecendreux, Giuseppe Plazzi, et al. · Sleep Medicine · 27

Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET

2020 · Pablo Rusjan, Pamela Sabioni, et al. · British Journal of Pharmacology · 21

Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans

2018 · Patricia Di Ciano, Esmaeil Mansouri, et al. · Neuropsychopharmacology · 18

PDF

Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study

2015 · Rashmi R. Shah, Pierre Maison-Blanche, et al. · European Journal of Clinical Pharmacology · 16

A Randomized, Double-Blind, Double-Dummy, Single-Dose, Crossover Trial Evaluating the Efficacy and Safety Profiles of Two Dose Levels (12 and 24 μg) of Formoterol-HFA (pMDI) vs. Those of a Dose Level (24 μg) of Formoterol-DPI (Foradil®/Aerolizer™) and of Placebo (pMDI or Aerolizer) in Moderate to Severe Asthmatic Patients

2005 · J. Bousquet, E. Guenolé, et al. · Respiration · 12

A Randomized, Double-Blind, Double-Dummy, Safety Crossover Trial Comparing Cumulative Doses up to 96 μg of Formoterol Delivered via an HFA-134a-Propelled pMDI vs. Same Cumulative Doses of Formoterol DPI and Placebo in Asthmatic Patients

2005 · M. Molimard, E. Guenolé, et al. · Respiration · 12

Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist

2016 · Rashmi R. Shah, Pierre Maison-Blanche, et al. · European Journal of Clinical Pharmacology · 11

Pharmacokinetics of Estradiol Valerate 2mg + Dienogest 2mg (Climodien?? 2/2) after Single and Repeated Oral Administration in Healthy Postmenopausal Women

2000 · H. Zimmerman, J.J. Thebault, et al. · Clinical Drug Investigation · 10

Bioavailability and cardiovascular effects of adrenaline administered by Anapen 500 μg auto‐injector in healthy volunteers

2022 · Thierry Duvauchelle, Philippe Robert, et al. · British Journal of Clinical Pharmacology · 8

PDF

The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects

2005 · R. Smith, S. Oliver, et al. · Journal of Clinical Oncology · 7

The pharmacodynamic effect on cardiac repolarization of combination single dose ZD6474 and ondansetron in healthy subjects

2005 · T. Hammett, S. Oliver, et al. · Journal of Clinical Oncology · 4

Comparative Bioavailability Study of Two Oral Omeprazole Formulations after Single and Repeated Administrations in Healthy Volunteers

1998 · T Duvauchelle, L Millerioux, et al. · Clinical Drug Investigation · 3

766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study

2023 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 2

Comparative Bioavailability of Two Oral Nimodipine Formulations after Administration to 24 Healthy Volunteers

1999 · V Gualano, B Ntsikoussalabongui, et al. · Clinical Drug Investigation · 2

759-P: Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study

2025 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 1

Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations

2023 · Francis M. Dijkstra, Rob G. J. A. Zuiker, et al. · British Journal of Clinical Pharmacology · 1

PDF

765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

2023 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 1

Pitolisant in combination with other medications for the management of narcolepsy

2019 · K. Doghramji, C. Davis, et al. · Sleep Medicine · 1

SAT-448 A 10-week, randomized, double blind, placebo-controlled exploratory proof of concept study of Utreglutide (GL0034) in individuals with overweight and obesity

2025 · Rajamannar Thennati, Vinod Burade, et al. · Journal of Hepatology

Works count: 36

Citation count: 535

H-index: 12

I10-index: 14